AbbVie, Genmab’s Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3
AbbVie and Genmab's Epkinly reduced disease progression or death risk by 51% in a Phase 3 trial for frontline DLBCL treatment, exceeding expectations. The study enrolled 900 patients and showed significant improvement over R-CHOP alone. Genmab's shares rose 11% following the data release. Epkinly is already approved for later-stage treatment and could compete with Roche's Polivy and Incyte's Monjuvi if approved for first-line use.
How this was made
The 30-second read
Why it matters
The data could drive label expansion, increase sales forecasts, and boost both companies' valuations.
Market read
First‑line DLBCL trial success is a material catalyst for both stocks and may influence competitor strategies.
What to watch
Potential competition from Roche's Polivy and Incyte's Monjuvi may limit market share.
Background
Phase 3 EPCORE DLBCL‑2 trial of Epkinly + R‑CHOP showed a 51% reduction in progression risk, surpassing analyst expectations.
Ticker impact
AbbVie announced Phase 3 data showing Epkinly reduces progression risk by 51% in frontline DLBCL, exceeding expectations.
upward pressure as investors price in potential first‑line indication and future sales uplift
Phase 3 readout exceeds analyst expectations and could lead to regulatory approval for a larger market.
Market effects
May accelerate first‑line bispecific antibody development across oncology sector.
Positive for US and European biotech markets where AbbVie and Genmab are listed.
Sets a new efficacy benchmark for DLBCL treatment worldwide.
Counterpoint
If regulatory review is delayed or safety concerns emerge, the rally could be short‑lived.
Key entities
- CompanyAbbVie
US‑listed biopharma partner developing Epkinly.
- CompanyGenmab
Danish biotech co‑developer of Epkinly.
